Pelacarsen Lowered the Biomarker. It Did Not Save Lives. Now What?
Novartis's pelacarsen hit its Lp(a) target in 8,323 patients but missed the cardiovascular endpoint entirely, exposing a $6B assumption...
Novartis's pelacarsen hit its Lp(a) target in 8,323 patients but missed the cardiovascular endpoint entirely, exposing a $6B assumption...
Obinutuzumab β's Phase 3 trial shows 93.1% relapse risk reduction in AQP4+ NMOSD, forcing a rethink of how rare...
The SYNCHRONIZE-MASLD Phase 3 trial in Nature Medicine shows survodutide cutting liver fat by 64.3% vs placebo — here's...
AstraZeneca's Phase 3 benralizumab trial in hypereosinophilic syndrome just delivered one of the cleanest efficacy signals in rare disease...